Premium
Ocular hypotensive effects of medifoxamine.
Author(s) -
Saleh S,
Turner P
Publication year - 1992
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1992.tb04136.x
Subject(s) - miosis , timolol , dopamine , pharmacology , volunteer , medicine , reuptake , intraocular pressure , anesthesia , drug , serotonin , ophthalmology , biology , receptor , agronomy
Medifoxamine is a novel monoamine re‐uptake inhibiting antidepressive drug which preferentially inhibits dopamine reuptake. In human volunteer studies it has been found to reduce significantly intraocular pressure after single oral doses of 300‐1000 mg, and to produce a small but statistically significant miosis. Its maximal ocular hypotensive action was less than that of oral timolol 20 mg.